Company intelligence / Profile preview

LittDD Medicines

Hangzhou, Zhejiang, Chinachinesebiotech.com ↗

Ownership: Private
Development stage: Other

Overview

LittDD Medicines is advancing a pipeline of orally available small molecules that target multiple critical tumor growth and survival pathways. Their lead asset, LIT0814, is in Phase 1 clinical trials for esophageal cancer and CRC. Another candidate, LIT0922, is an mTORC2 selective inhibitor entering clinical trials by the end of 2024. The company’s approach focuses on biomarker-selected patient populations to improve efficacy and reduce resistance

Therapeutic areas: Women's HealthOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on LittDD Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LittDD Medicines.

Explore the full profile